Clearly, it remains to be addressed how the double effects of the TKI at inhibiting CSF-1R expressed by both tumor-infiltrating immune components and by the tumor cells is balanced in more clinically relevant settings and how this can be exploited, therapeutically. This evidence concerns the gene CSF1R and neoplasm.